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Chronic obstructive pulmonary disease
(COPD) is a growing global epidemic that
is particularly important in developing
countries. Morbidity and mortality from
COPD will rise as populations age and
mortality from cardiovascular and infec-
tious diseases falls. Whereas cigarette smok-
ing is the commonest cause of COPD in
developed countries, COPD is also seen in
nonsmokers, particularly in developing
countries, yet very little is know about this
form of COPD. COPD is primarily
characterized by the presence of airflow
limitation resulting from inflammation and
remodelling of small airways and is often
associated with lung parenchymal destruc-
tion or emphysema. It is increasingly
recognised that COPD extends beyond
the lung and that many patients have
several systemic manifestations that can
further impair functional capacity and
health-related quality of life [1]. In addition,
COPD is associated with several other
diseases, such as cardiovascular diseases,
osteoporosis, diabetes, and metabolic syn-
drome, more commonly than expected by
chance. These associations are greater than
expected from common aetiological factors,
such as smoking, suggesting that these
comorbidities may be causally associated
with the mechanisms of COPD. Systemic
effects and comorbidities of COPD increase
both the risks of hospitalisation and mor-
tality and the costs, and are therefore a
topic of increasing concern [2]. Indeed,
cardiovascular disease and lung cancer are
the commonest causes of death in patients
with COPD [2,3]. Although comorbidities
a r em o r ec o m m o n l ys e e ni na s s o c i a t i o n
with severe COPD, they may also be
associated with milder or earlier disease.
Mechanisms: The Role of
Systemic Inflammation
The mechanism linking COPD to sys-
temic manifestations and comorbidities is
not yet certain, but a potential mechanism
is systemic inflammation. Other possible
mechanisms (which are not mutually exclu-
sive) include shared genetic predispositions,
physical inactivity secondary to airway
obstruction, and chronic hypoxia. Several
inflammatory cytokines, including tumour
necrosis factor-a (TNFa), interleukin(IL)-6,
CXCL8 (IL-8), and IL-18, and acute phase
proteins, such as C-reactive protein (CRP),
serum amyloid A, and fibrinogen, are
increased within the circulation of patients
with COPD, particularly during exacerba-
tions [4]. The cytokines that are increased
in the circulation are also increased in
sputum and bronchoalveolar lavage fluid of
COPD patients, suggesting that the system-
ic cytokines represent an overspill of
inflammatory mediators from the peripher-
al lung (Figure 1) [1]. Since the circulating
cytokines found in COPD are common to
many inflammatory diseases, this mecha-
nism is difficult to verify. Recently, howev-
er, surfactant protein D, which is produced
exclusively by type II pneumocytes, were
found to be elevated in the circulation of
COPD patients, providing more direct
evidence for the overspill hypothesis [5].
However, there is not a close correlation
between the concentration of mediators in
sputum and blood, suggesting that other
factors are also involved. Physical inactiv-
ity as a consequence of progressive airflow
limitation may be an important factor in
promoting some comorbidities, such as
skeletal muscle weakness, osteoporosis,
and cardiovascular disease. There is also
increasing evidence that emphysema rep-
resents accelerated ageing of the lung and
that many of the comorbidities associated
with COPD, such as osteoporosis, cardiac
failure, and diabetes, are also diseases of
accelerated ageing and may be a conse-
quence of reduced synthesis of anti-ageing
molecules, such as sirtuins [6]. There may
be genetic factors that increase suscepti-
bilities to develop certain comorbidities
and there may be common genetic factors
linked to increased susceptibilities of
smokers to develop COPD. Another view
is that several diseases may contribute to
systemic inflammation and that this affects
the lung, resulting in worsening of the
structural changes of COPD [7]. Howev-
er, COPD can certainly occur without any
evidence of systemic inflammation, so this
hypothesis seems less likely.
COPD and Cardiovascular
Disease
Cardiovascular disease is a major cause
of mortality and morbidity in patients with
COPD. Although there are common
causal factors including smoking and
sedentarism, the increase in cardiovascular
disease is independent of these known risk
factors [2]. Recently, several studies have
shown that COPD patients have increased
arterial stiffness, which may explain the
epidemiological link between reduced
FEV1 (forced expiratory volume in 1 sec-
ond) and cardiovascular mortality [8]. The
mechanism for increased arterial stiffness
is not yet certain but could reflect systemic
endothelial cell dysfunction as a result of
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study was not able to demonstrate any
defect in endothelial function in COPD
patients with arterial stiffness, suggesting
that it may be due to an abnormality in
the arterial wall [9]. Systemic inflamma-
tion may predispose to atherosclerotic
plaques, which may account for the high
prevalence of myocardial infarction in
patients with COPD.
Chronic heart failure is also common
amongst COPD patients and in a recent
study over 20% of patients were found to
have undiagnosed left ventricular failure
by magnetic resonance imaging [10]. It
may be difficult to diagnose heart failure in
COPD patients because of the overlap in
symptoms, but measurement of plasma B-
type natriuretic peptide concentrations is
useful in detecting cardiac failure.
COPD and Metabolic Diseases
There is an increased risk of diabetes in
COPD patients [2]. Systemic inflamma-
tion, and particularly the proinflammatory
cytokines TNF-a and IL-6, may induce
insulin resistance. Metabolic syndrome,
characterised by central obesity, diabetes,
hypertension, and hyperlipidaemia, is also
known to occur with COPD. In a recent
study of COPD patients, metabolic syn-
drome was found in almost half of the
patients irrespective of disease stage and
was associated with increased markers of
systemic inflammation, including IL-6,
CRP, and fibrinogen [11]. In an epidemi-
ological study in China metabolic syn-
drome was identified in approximately
20% of patients with COPD, and this
correlated most closely with central obesity
[12]. Cachexia and weight loss has also
been associated with COPD, particularly
in severe disease and may be related to
increased concentrations of certain cyto-
kines, such as TNF-a. There is selective
loss of skeletal muscle, measured as fat-free
mass, and this is associated with a selective
loss of type IIA fibres. To some extent this
muscle wasting is explained by physical
inactivity and tends to be more pro-
nounced in the lower limbs, but there
may also be metabolic mechanisms such as
systemic oxidative stress and circulating
inflammatory cytokines that accelerate this
loss.
COPD and Bone Disease
Several studies have shown a very high
prevalence of osteoporosis and low bone
mineral density in patients with COPD,
even with milder stages of disease [13]. In
a cross-sectional study the prevalence of
osteoporosis was 75% in patients with
GOLD (Global Initiative on Obstructive
Lung Disease) stage IV disease and was
strongly correlated with reduced fat-free
mass, especially in women. Vertebral
compression fractures are relatively com-
mon amongst COPD patients, and the
resultant increased kyphosis may further
reduce pulmonary function. There are
shared risk factors between COPD and
osteoporosis, including cigarette smoking
Figure 1. Patients with COPD have peripheral lung inflammation that may spill over into the systemic circulation, leading to
skeletal muscle weakness and cachexia and increasing propensity to cardiovascular, metabolic, and bone diseases, and
depression. There is an increase in circulating cytokines, including IL-1b, IL-6, IL-18, and TNFa, as well as acute-phase proteins, such as CRP and
serum amyloid A. Peripheral lung inflammation may also increase the risk of developing lung cancer. There may be genetic predisposition to
developing COPD in smokers, which may be shared with genetic susceptibility to comorbid diseases. Airway obstruction reduces physical activity and
causes hypoxia, which may contribute to skeletal muscle weakness as well as to comorbid diseases.
doi:10.1371/journal.pmed.1000220.g001
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inhaled corticosteroids, but COPD itself
appears to be a risk factor for osteoporosis
and osteopenia. Osteoporosis is also linked
to arterial stiffness as well as COPD and
this has suggested a common aetiology as a
result of systemic inflammation [8]. In-
flammatory cytokines, such as IL-1b, IL-6,
and TNF-a, inhibit osteoclasts and may
promote bone resorption.
COPD and Psychiatric Diseases
Anxiety and depression are remarkably
common in COPD patients due in part to
their social isolation, but appear to be more
common than in other chronic disabling
diseases. Major depression that requires
medical intervention occurs in 20%–40%
of COPD patients, but there are wide
variations in the incidence of depression, as
different assessment tools have been used,
and the diagnosis may be overlooked, as
there is an overlap of symptoms. Depres-
sion worsens health status and increases
mortality in COPD patients and it should
therefore be treated appropriately. The
mechanisms of depression are multifactori-
al, but there is growing evidence that
systemic inflammation may result in de-
pression and IL-6 appears to play a
particularly important role in humans and
in animal models of depression.
Cognitive dysfunction is also increasing-
ly recognised in patients with COPD,
especially in severe disease, and this may
have an important impact on self man-
agement and adherence to therapy [14].
COPD and Lung Cancer
Patients with COPD are 3 to 4 times
more likely to develop lung cancer than are
smokers with normal lung function. Lung
cancer is found in 40%–70% of patients
with COPD, particularly in severe disease,
and is a common cause of death in COPD
patients [15]. Lung cancer is also more
common in patients with COPD who have
never smoked in a large prospective trial of
almost half a million nonsmokers [16]. The
most likely explanation for the increased
risk of lung cancer in COPD is the presence
of chronic inflammation, with increased
production of growth factors and angiogen-
ic factors. Stopping smoking in COPD
patients reduces but does not eliminate the
risk of lung cancer, probably because
inflammation persists even after smoking
cessation [17].
Implications for Management
The recognition that COPD is a
multidimensional disease with numerous
comorbidities and systemic effects has
several important consequences for long-
term management of this disease. Al-
though there are national and internation-
al guidelines for the management of
COPD, they deal mainly with the pulmo-
nary aspects of the disease and do not
address the management of comorbid
diseases, which are managed by other sets
of guidelines drawn up by different groups
of specialists. There needs to be more
integration of these guidelines, indicating
how comorbidities are best managed in
COPD patients and what the best choice
of therapy should be, taking into account
drug interactions and propensity to ad-
verse effects as a result of the comorbid
disease. In turn, other specialists should be
aware that COPD is commonly comorbid
with cardiovascular and metabolic diseas-
es, and this may only become apparent if
spirometry is performed, as COPD is very
often undiagnosed in these patients. In
other words, a more integrated approach
to management is required.
It is now emerging that several treatments
used in comorbid diseases may have bene-
ficial effects in COPD. Observational studies
suggest that COPD patients treated with
statins, angiotensin-converting enzymes, and
beta-blockers may have improved survival
and reduced hospitalisation from exacerba-
tions [1]. However, because of selection
biases inherent in these studies, it is
important to conduct placebo-controlled
randomised clinical trials to determine where
these treatments may improve COPD
outcomes. A large trial of statin therapy
in COPD patients is currently underway
to address this issue (ClinicalTrials.gov
NCT01061671). Peroxisome proliferator ac-
tivator receptor (PPAR)-c agonists, devel-
oped to treat diabetes, may also have
therapeutic potential in COPD as anti-
inflammatory and anti-fibrotic treatments.
Treatments currently used for manage-
ment of COPD might have effects on
systemic manifestations and comorbidities,
but this has not often been clearly assessed.
Smoking cessation and reduction of expo-
sure to biomass fuel smoke are important
for their beneficial effects on comorbidities
as well as pulmonary disease. In a large
trial of the anticholinergic bronchodilator
tiotropium bromide in COPD patients
(UPLIFT) there was a significant reduc-
tion in cardiovascular mortality [18]. By
contrast, an inhaled corticosteroid had no
effect on cardiovascular mortality [3].
Several new treatments for COPD are
now in development and, in addition to
any effect on the pulmonary disease, it will
be important to assess whether these
treatments affect systemic manifestations
and comorbid diseases.
Conclusions and Future
Directions
COPD is a multidimensional disease,
with several systemic manifestations and
associations with a number of comorbid
diseases. The most likely link between
COPD and these extrapulmonary condi-
tions is spillover of inflammatory media-
tors from the lung, as systemic inflamma-
tion is associated with skeletal muscle
wasting and cachexia as well as with
cardiovascular, metabolic, and bone dis-
eases. More research is needed to under-
stand the links between these diseases and
to search for common treatable compo-
nents. It seems likely that treatments, such
as statins, that are already used to manage
cardiovascular and metabolic diseases
might also provide benefit in COPD
patients, although it is important that
randomised placebo-controlled trials be
conducted to confirm this possibility. It is
important to consider how the existence of
a comorbid disease may affect the man-
agement of the patient who also has
COPD. Guidelines are needed that rec-
ognise the association of these various
diseases and provide advice on manage-
ment, as well as defining questions for
future clinical research. In turn, it is
important for specialists in nonpulmonary
areas to recognise that COPD may
commonly occur in association with cer-
tain diseases in their speciality and to make
the diagnosis using spirometry so that
appropriate treatment may be instituted.
Treatments already used in the treatment
of COPD might also be beneficial in some
comorbid diseases. New therapies should
also be considered as potentially beneficial
to systemic manifestations and comorbid-
ities. For example, an effective inhaled
anti-inflammatory therapy may improve
comorbidities by reducing the overspill of
inflammatory mediators from the lung
that contribute to systemic inflammation.
Alternatively, an oral anti-inflammatory
treatment, as well as suppressing inflam-
mation on the respiratory tract, may
directly reduce systemic inflammation. It
is clear that much more clinical and basic
research is needed to understand the
complexity of COPD so that more effec-
tive management of COPD and its various
comorbidities is possible in the future.
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